CA2642216A1 - New crystal forms and pharmaceutical compositions of (+)-r-zileuton - Google Patents

New crystal forms and pharmaceutical compositions of (+)-r-zileuton Download PDF

Info

Publication number
CA2642216A1
CA2642216A1 CA002642216A CA2642216A CA2642216A1 CA 2642216 A1 CA2642216 A1 CA 2642216A1 CA 002642216 A CA002642216 A CA 002642216A CA 2642216 A CA2642216 A CA 2642216A CA 2642216 A1 CA2642216 A1 CA 2642216A1
Authority
CA
Canada
Prior art keywords
crystalline form
single crystalline
zileuton
pharmaceutical composition
condition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002642216A
Other languages
English (en)
French (fr)
Inventor
Jason A. Hanko
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Chiesi USA Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2642216A1 publication Critical patent/CA2642216A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
    • C07D333/54—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • C07D333/58—Radicals substituted by nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Vascular Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Otolaryngology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Toxicology (AREA)
  • Urology & Nephrology (AREA)
  • Virology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA002642216A 2006-02-21 2007-02-21 New crystal forms and pharmaceutical compositions of (+)-r-zileuton Abandoned CA2642216A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US77557906P 2006-02-21 2006-02-21
US60/775,579 2006-02-21
PCT/US2007/004488 WO2007098189A2 (en) 2006-02-21 2007-02-21 New crystal forms and pharmaceutical compositions of (+) -r-zileuton

Publications (1)

Publication Number Publication Date
CA2642216A1 true CA2642216A1 (en) 2007-08-30

Family

ID=38437967

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002642216A Abandoned CA2642216A1 (en) 2006-02-21 2007-02-21 New crystal forms and pharmaceutical compositions of (+)-r-zileuton

Country Status (6)

Country Link
US (1) US8003684B2 (cg-RX-API-DMAC7.html)
EP (2) EP2001861A2 (cg-RX-API-DMAC7.html)
JP (1) JP2009527484A (cg-RX-API-DMAC7.html)
AU (1) AU2007217770B2 (cg-RX-API-DMAC7.html)
CA (1) CA2642216A1 (cg-RX-API-DMAC7.html)
WO (1) WO2007098189A2 (cg-RX-API-DMAC7.html)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8445437B2 (en) * 2006-07-27 2013-05-21 The Brigham And Women's Hospital, Inc. Treatment and prevention of cardiovascular disease using mast cell stabilizers
CA2674492A1 (en) * 2007-01-05 2008-07-17 Cornerstone Therapeutics Inc. Method for the treatment of conditions associated with increased 5-lipoxygenase and/or leukotriene activity
WO2009045291A2 (en) * 2007-09-28 2009-04-09 The Brigham And Women's Hospital, Inc. Mast cell stabilizers in the treatment of obesity
CN107233337A (zh) 2009-04-29 2017-10-10 阿马里纳药物爱尔兰有限公司 含有epa和心血管剂的药物组合物以及使用其的方法
EP2747762B1 (en) * 2011-08-23 2015-07-01 Cornerstone Therapeutics Inc. Use of zileuton for the treatment of nasal polyps in cystic fibrosis patients
US9855243B2 (en) 2013-10-30 2018-01-02 Qurient Co., Ltd. Topical anti-inflammatory pharmaceutical composition with zileuton cream formulation
KR101462474B1 (ko) * 2013-10-30 2014-11-19 주식회사 큐리언트 질레우톤 크림 제형의 국소용 항염증 약학적 조성물
KR20170012332A (ko) * 2014-06-20 2017-02-02 아비라겐 테라퓨틱스, 인코포레이티드 [2-[1-(6-메틸-3-피리다지닐)-4-피페리디닐]에톡시]-3-에톡시-1,2-벤즈이속사졸의 무수 결정성 유리 염기 형태

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US279263A (en) * 1883-06-12 Eobeet t
ES2059408T3 (es) * 1987-02-10 1994-11-16 Abbott Lab Un proceso para la preparacion de un compuesto.
EP0697868A4 (en) * 1993-05-10 1998-04-08 Sepracor Inc THERAPIES AND COMPOSITIONS USING OPTICALLY PURE (+) - ZILEUTON
JPH09500139A (ja) 1993-07-14 1997-01-07 スミスクライン・ビーチャム・コーポレイション ヒドロキシルアミンの酸付加塩の合成法

Also Published As

Publication number Publication date
AU2007217770A1 (en) 2007-08-30
EP2001861A2 (en) 2008-12-17
WO2007098189A3 (en) 2008-04-03
EP2409973A1 (en) 2012-01-25
US20070244185A1 (en) 2007-10-18
JP2009527484A (ja) 2009-07-30
AU2007217770B2 (en) 2011-09-08
US8003684B2 (en) 2011-08-23
WO2007098189A2 (en) 2007-08-30

Similar Documents

Publication Publication Date Title
US8003684B2 (en) Crystal form and pharmaceutical compositions of (+)-R-zileuton
CN110577534B (zh) 苯甲酰氨基吡啶衍生物的盐及其在药物中的应用
US8859567B2 (en) Hydrate of 1-{(2S)-2-amino-4-[2,4-bis(trifluoromethyl)-5,8-di-hydropyrido[3,4-D]pyrimidin-7(6H)-yl]-4-oxobutyl}-5,5-difluoro-piperidin-2-one tartrate
US10301287B2 (en) Solid forms of cenicriviroc mesylate and processes of making solid forms of cenicriviroc mesylate
CN107400134A (zh) 嘌呤衍生物的结晶形式
KR20140026379A (ko) 리팍시민의 형태 및 이의 용도
TW202235081A (zh) Bcl的葡甲胺鹽晶形固體抑制劑及其製備方法和用途
CN110577541A (zh) 苯甲酰氨基吡啶衍生物的盐及其在药物中的应用
CN112135832A (zh) 化合物的晶型和制备化合物的晶型的方法
WO2023160727A1 (zh) 吲唑类化合物用于治疗银屑病的用途
JP2025508746A (ja) 化合物の多形形態及び多形形態を生成する方法
US12479808B2 (en) Salts or co-crystals of {2-[3-cyclohexyl-3-(trans-4-propoxy-cyclohexyl)-ureido]-thiazol-5-ylsulfanyl}-acetic acid and uses thereof
US9303036B2 (en) Crystalline asenapine hydrochloride salt forms
ES2926790T3 (es) Solvato de dietilamina del inhibidor del transportador de sodio-glucosa, y método de preparación y aplicación del mismo
TWI848622B (zh) Vanin酶抑制劑的鹽型、晶型及其製備方法和用途
US20200308176A1 (en) Co-crystals of neflamapimod (vx-745)
US20040058901A1 (en) Crystalline ethanolate solvate form of zafirluskast process for manufacture and pharmaceutical compositions thereof
EP3978476A1 (en) Solid form of aromatic compound and preparation method therefor
US20130012444A1 (en) Crystalline solvates of 6-(piperidin-4-yloxy)-2h-isoquinolin-1-one hydrochloride
US20250059202A1 (en) Crystal form of fused ring derivative, and preparation method therefor and use thereof
US20260048036A1 (en) Crystalline forms of a glucosylceramide synthase inhibitor and uses thereof
KR20180124428A (ko) 결정형 사쿠비트릴 헤미나트륨염, 이의 제조방법 및 이를 포함하는 약학 조성물
TW202615004A (zh) 喹啉cGAS拮抗劑化合物之固體形式及鹽
WO2026098459A1 (zh) 一种取代的2-(吡咯烷-3-基)乙酸衍生物的晶型及其制备方法和用途
RU2603962C2 (ru) Новый класс селективных агонистов соматостатиновых рецепторов

Legal Events

Date Code Title Description
EEER Examination request
FZDE Dead

Effective date: 20140716